David Mehalick
2023
In 2023, David Mehalick earned a total compensation of $360K as Chairman, CEO and President at Coeptis Therapeutics Holdings, which was about the same as previous year.
Compensation breakdown
| Salary | $360,000 |
|---|---|
| Total | $360,000 |
Mehalick received $360K in salary, accounting for 100% of the total pay in 2023.
Rankings
In 2023, David Mehalick's compensation ranked 2,361st out of 2,978 executives tracked by ExecPay. In other words, Mehalick earned more than 20.7% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 2,361 out of 2,978 | 21st |
Division Manufacturing | 1,325 out of 1,637 | 19th |
Major group Chemicals And Allied Products | 776 out of 906 | 14th |
Industry group Drugs | 757 out of 869 | 13th |
Industry Biological Products, Except Diagnostic Substances | 191 out of 211 | 10th |
Source: SEC filing on November 14, 2024.
Mehalick's colleagues
We found four more compensation records of executives who worked with David Mehalick at Coeptis Therapeutics Holdings in 2023.
2023
Daniel Yerace
Coeptis Therapeutics Holdings
Vice President of Operations
2023
Colleen Delaney
Coeptis Therapeutics Holdings
Chief Financial Officer
2023
Brian Cogley
Coeptis Therapeutics Holdings
Chief Financial Officer
2023
Christine Sheehy
Coeptis Therapeutics Holdings